New Zofran (ondansetron) Birth Defect Case Filed by Leading Firm Grant & Eisenhofer

Cases from all over the country continue to be filed against GlaxoSmithKline (“GSK”) over its anti-nausea drug Zofran (ondansetron)—one of the latest by the law firm that has been at the forefront of the litigation, Grant & Eisenhofer P.A. On behalf of Michelle Lynne Forbes and her son, Grant & Eisenhofer’s complaint filed in the Southern District of Illinois is alleging that GSK marketed Zofran (ondansteron) “off label” for uses unapproved by the FDA, namely touting the drug to be safe to use in pregnant women despite its link to causing birth defects such as heart malformations and cleft palate. In this particular case, Forbes is seeking justice after her son was born in 2009 with a ventricular septal defect due to Zofran (ondansetron) exposure in utero.

Grant & Eisenhofer remains one of the leading firms investigating GSK’s misconduct.  There are now 36 cases alleging similar claims pending in 20 courts nationwide.  The cases are slated to be centralized in a multi-district litigation, or MDL.

Real Time Analytics